
All pre-licensing clinical safety trials of PCV15 in adults compared the vaccine to PCV13. In clinical trials, common side effects reported following vaccination included injection site pain, redness, and swelling,...

According to the CDC, approximately 50 percent of individuals who receive the pneumococcal polysaccharide vaccine (PPSV23) experience pain and redness at the injection site. Muscle aches, fever, and more severe...

Adverse reactions following administration of PCV13 differed by dose in the series and age of the recipient. In children, the most commonly reported reactions included irritability, drowsiness, loss of appetite,...

The continued emergence of non-vaccine types pneumococcal strains prompted the development of new pneumococcal vaccines. Merck received FDA approval in July 2021 for a 15-valent pneumococcal vaccine, PCV15, for use...

Information on pneumococcal conjugate vaccine efficacy found in the Prevnar 13(PCV13) product insert reports information pertaining to the original PCV vaccine, Prevnar (PCV7). PCV7 was reported to be 100 percent...

The initial pre-licensing clinical trials of a pneumococcal capsular polysaccharide involved a comparison study of the effectiveness of a 6-valent polysaccharide vaccine against a 12-valent polysaccharide vaccine. The study involved...

In June 2021, Wyeth pharmaceuticals received FDA approval for Prevnar 20 (PCV20) vaccine, a 20-valent pneumococcal conjugate vaccine, which added seven additional strains (8, 10A, 11A, 12F, 15B, 22F, and...

In December of 2011, the FDA approved the expanded use of PCV13 under an “Accelerated Approval” process to include adults 50 years of age and older. The “Accelerated Approval” process...

Vaccine manufacturers responded to the emergence of multiple antibiotic-resistant strains of S. pneumoniae by introducing new pneumococcal vaccines containing additional strains. In March 2009, Synflorix (PCV10), a 10-valent pneumococcal conjugate...

As pneumococcal polysaccharide vaccines were found to be ineffective in children under the age of two, vaccine development continued. Pneumococcal related deaths were reported to be uncommon among children except...